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OBJECTIVES: Health care utilization and costs may be elevated
among patients with C-ONLY and IBS+C. Migraine is an appro-
priate comparator because it is chronic, costly, and non-
gastrointestinal. Health care utilization and costs were evaluated
for these three groups. METHODS: A large US health plan
claims database was retrospectively analyzed from January 2003
through December 2005. Three mutually exclusive cohorts were
identiﬁed: 1) C-ONLY: ICD-9 564.0x (N = 91,632); 2) IBS+C:
ICD-9 564.1 and 564.0x (N = 10,952); and 3) Migraine: ICD-
9 346.xx (N = 101,418). Per patient use and costs (charged
amounts) of medical services and prescriptions were assessed
over a period of 3 months prior to and 9 months following ﬁrst
diagnosis. Patients had continuous health plan enrollment during
this period. RESULTS: Total health care charges were $15,808
and $16,378 for patients with C-ONLY and IBS+C compared to
$10,405 among patients with migraine (difference $5403 and
$5,973, both P < 0.0001). Inpatient charges were approximately
2.5 times higher for the C-ONLY cohort and 1.7 times higher
for the IBS+C cohort compared to migraine ($5112 and $3,625,
vs. $2093; both P < 0.0001). Both cohorts had higher charges
for ofﬁce visits compared to migraine ($2460 and $3,050, vs.
$2282; both P < 0.0001). Charges for hospital outpatient ser-
vices were $3913 and $4738 for patients with C-ONLY and
IBS+C, respectively, compared to $2784 for migraine (both P <
0.0001), while charges for other ancillary services were $2578
and $2627 for C-ONLY and IBS+C, respectively, compared to
$1444 for migraine (both P < 0.0001). Prescription drug charges
were slightly lower for C-ONLY, but higher for IBS+C compared
to migraine ($1438 and $2053 vs. $1551; both P < 0.0001).
Charges for ER visits were higher for both cohorts compared to
migraine ($307 vs. $251, P < 0.0001 and $284 vs. $251, P =
0.0059). CONCLUSION: C-ONLY and IBS+C are costly con-
ditions that present greater economic burden to payers compared
to migraine. Institutional costs are primary drivers for constipa-
tion expenditures.
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COST OF PATIENT CARE IN PATIENTS WITH CROHN`S
DISEASE IN BRAZIL: PUBLIC HEALTH PERSPECTIVE
Araujo G, Fonseca M
Axia.Bio Consulting, São Paulo, Brazil
OBJECTIVES: Because of its long duration, Crohn`s disease
(CD) causes high use of health services and high lifetime costs
for medical care. The aim of the present study was to measure
the annual costs of patients with CD from the Brazilian public
heath perspective and to identify potentially relevant determi-
nants of costs. METHODS: Thirty one gastroenterologists from
southeast Brazil prospectively evaluated all their CD patients
during two months. They used a structured questionnaire specif-
ically developed to evaluate resource use by patients with CD.
Costs of medical services (diagnostics and treatment) were con-
sidered as well as costs of medication. Resource use was valued
using government reimbursement for hospital services and gov-
ernment tender prices for drugs. RESULTS: 221 patients were
evaluated. The mean annual cost of one CD patient was R$
2.239,67, including medication, physician, laboratory, diagnos-
tic procedures, hospitalization and surgery costs. Medication,
hospitalization, surgery and laboratory/ diagnostic procedures
accounted, respectively for 79%, 18%, 2% and 1% of the total
annual costs. Mesalazine was the most used drug to initiate CD`s
treatment (59% of the times). Although mesalazine is deemed to
be more expensive than sulfasalazine, there was no statistical dif-
ference between the costs of the patients treated with mesalazine
and sulfasalazine. In fact, due to differences in the mean dosage
of theses drugs, mesalazine daily cost is lower than sulfasalazine.
CONCLUSION: This is the ﬁrst time that CD treatment costs
have been demonstrated from the Brazilian public health per-
spective. Considering that there was no statistical difference in
total costs among patients taking mesalazine and sulfasalazine,
and that medications represent more than 70% of total CD treat-
ment annual costs in the public Brazilian health care system, the
use of mesalazine may represent a reduction factor in the ﬁnan-
cial resource expenditure for the treatment of CD.
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PREVENTING NSAID ASSOCIATED GASTROINTESTINAL
COMPLICATIONS IN CANADA
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OBJECTIVES: To investigate the potential impact of non-
adherence resulting from multiple daily dosing on cost-utility of
gastrointestinal prophylaxis strategies in preventing NSAID
associated gastrointestinal complications. METHODS: Two
decision analytical models (TreeAge 2005) were developed—one
model incorporating non-adherence resulting from multiple daily
dosing and another model that does not. Each model evaluates
the cost-utility of gastrointestinal prophylaxis in a hypothetical
cohort of patients’ age ≥65 years beginning a 6 month course of
NSAIDs. Patients entering each model were treated with either:
(1.) No Prophylaxis, (2.) Proton Pump Inhibitors (generic
omeprazole od) (3.) misoprostol (200 ug qid), (4.) ranitidine (300
mg bid). Average adherence to therapy: od = 79% ± 14%, bid =
69% ± 15% and qid = 51% ± 20% were obtained from a sys-
tematic review of studies using electronic monitoring devices.
Costs were from the perspective of a 3rd party payer of a Cana-
dian provincial seniors’ drug plan. Cost-Utility was measured 
in terms of cost per quality adjusted life year (QALY) gained, 
relative to no prophylaxis. Probabilistic sensitivity analysis 
using Monte Carlo Simulation was used to generate uncertainty
of results, along with cost-effectiveness acceptability curves.
RESULTS: Misoprostol (200 ug qid) has a greater likelihood
(69.2%) than generic omeprazole (30.8%) of being the optimal
cost-effective strategy at a willingness to pay (WTP) of $50,000
per QALY in the model that does not incorporate non-adherence
resulting from multiple daily dosing. In the model that incorpo-
rates non-adherence resulting from multiple daily dose regimens,
generic omeprazole has a greater likelihood (94.8%) than miso-
prostol (5.2%) of being the optimal cost-effective strategy at a
WTP of $50,000 per QALY. CONCLUSION: Cost-utility results
are sensitive to non-adherence resulting from multiple-daily
dosing. Previous economic models in this area have not incor-
porated this in the analysis. Markov modeling or discrete event
simulation may be better suited to incorporate non-adherence
rates of therapies.
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OBJECTIVES: To describe the relationship between symptoms
of gastroesophageal reﬂux disease (GERD) and costs for work
productivity loss, physician/specialist visits, emergency room
visits, hospitalisations, and prescribed GERD-related medica-
tion. METHODS: An exploratory database analysis was per-
formed on results from the 2004 National Health and Wellness
Survey. US respondents with self-reported symptoms of GERD
(n = 10,028, mean age: 52 years, 58% female) were age- and
sex-matched to controls without GERD symptoms (n = 10,028).
Respondents with GERD were classiﬁed by self-reported
symptom severity (mild, moderate or severe) and frequency (low
or medium-to-high: symptoms on <2 days or ≥2 days per week,
respectively). Productivity losses (absence from work and
reduced productivity while at work) were obtained using the
generic version of the Work Productivity and Activity Impair-
ment questionnaire, and were calculated as the mean difference
between employed respondents with GERD (n = 5505) and con-
trols (n = 6031). Costs were calculated by multiplying ﬁxed
approximate unit costs by self-reported productivity losses and
resource utilisation. RESULTS: Compared with controls, respon-
dents with GERD had greater costs per month for absence from
work (mean difference [MD]: $113 per employee), reduced pro-
ductivity while at work (MD: $283 per employee), physician/spe-
cialist visits (MD:$45), emergency room visits (MD: $7), and
hospitalisations (MD: $30). Monthly GERD-related medication
costs for respondents with GERD were $42. The mean differ-
ences in costs increased with increasing GERD symptom sever-
ity and/or frequency for all cost variables. The relative cost of
GERD medication decreased with increasing symptoms: for
example, when excluding productivity costs, GERD medication
constituted 40% of the mean difference in overall monthly costs
in patients with mild symptoms and a low frequency, but only
25% in patients with severe symptoms and a medium-to-high
frequency. CONCLUSION: Increasing severity and frequency of
GERD symptoms was found to be associated with higher overall
costs, while the relative importance of GERD medication costs
decreased.
GASTROINTESTINAL DISORDERS—Health Care Use &
Policy Studies
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HAVING YOUR CAKE AND EATING IT TOO: RESULTS FROM A
POLICY ANALYSIS OF A PROTON PUMP INHIBITOR
PREFERRED DRUG LIST
Martin BC, Karve SJ, Helm M
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OBJECTIVES: On May 18, 2005 the Arkansas Medicaid
program implemented an evidence-based Preferred Drug List
(PDL) recommendation for Proton Pump Inhibitors (PPIs).
Under the PDL program guidelines, esomeprazole and lansopra-
zole were made available as preferred agents to Medicaid recip-
ients without prior approval. Previously, all PPIs required prior
authorization and were not covered unless patients The objec-
tive of this study was to estimate the impact of this policy on PPI
expenditures and utilization as well as utilization of potential
substitute H2RAs. METHODS: This study utilized a time series
panel design to evaluate the impact of the policy using Arkansas
Medicaid administrative claims data obtained from January
2003 through August 2006. Auto-Regressive Integrated Moving
Average (ARIMA) time series models were speciﬁed using
monthly prescription expenditures and utilization in the pre-
policy period (January 2003–April 2005) to forecast expen-
ditures and utilization in the post-policy period. The Medicaid
payer perspective was used and all prescription costs were 
calculated based on the amount paid for each claim adjusted 
for product speciﬁc CMS rebates. RESULTS: The annual 
forecast expenditures for PPIs and H2RAs collectively for 
June 2005–May 2006 was $9,432,605 (95%CI: 8,747,983–
10,117,226) and observed expenditures were $4,555,592 indi-
cating that the prior approval policy change was associated with
a 52% reduction in GI antisecretory expenditures or $4,877,013
(95%CI: 4,192,391–5,561,635). Utilization of PPIs increased by
44% (3001 Rxs/month; 95%CI: 3695–2308) which more than
offset the 21% (1660 Rxs/month; 95%CI: 1199–2121) decrease
in utilization of H2RAs. CONCLUSION: Replacing step therapy
and prior authorization requirements with a preferred drug list
selection including supplemental rebates for this Medicaid
program signiﬁcantly lowered expected combined H2RA and
PPI prescription expenditures. Since utilization to antisecretory
therapy actually increased, increases in non-pharmacy costs or
negative outcomes are not anticipated.
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OBJECTIVES: Hospitalization is a major source of health care
costs for Crohn’s Disease (CD). This retrospective analysis of
clinical trial data examined the relationship between Crohn’s
Disease Activity Index (CDAI) scores and hospitalization risk.
METHODS: We analyzed data from the CHARM trial (adali-
mumab maintenance therapy) for 778 randomized patients (of
854 enrolled) with moderate to severe CD (baseline CDAI:
220–450) who were treated for up to 66 weeks. As a measure
of clinical efﬁcacy, CDAI scores were collected. Hospitalization
events were recorded as severe adverse events. While controlling
for patient demographic information, we applied a Cox propor-
tional hazard regression model to evaluate the relationship
between hospitalization risk and CDAI reduction or clinical
remission (CDAI < 150). CDAI and clinical remission were
imputed as time-varying covariates. Simulation was applied to
assess 1-year, all-cause and CD-related hospitalization rates.
RESULTS: A total of 157 patients were hospitalized, of which
112 were for CD-related reasons. Cox regression revealed that,
at any point in time, lower CDAI score was associated with
decreased risk of both all-cause hospitalization (hazard ratio
[HR] = 1.06 for every 10 points of CDAI increase, p < 0.01) and
CD-related hospitalization (HR = 1.08, p < 0.01). Simulation
study showed that a 70-point CDAI reduction throughout the
follow-up period reduced all-cause hospitalization risk by 28.3%
and CD-related hospitalization risk by 36.5% at year-end. Clin-
ical remission was associated with a signiﬁcant reduction in both
all-cause (HR = 0.52, p < .001) and CD-related hospitalizations
(HR = 0.37, p < .001). Simulations revealed that clinical remis-
sion was associated with a 43.7% decrease in the 1-year risk of
all-cause hospitalization and a 60.3% decrease in CD-related
hospitalization. CONCLUSION: Both lower CDAI score and
clinical remission are associated with signiﬁcantly reduced hos-
pitalization risk for CD patients.
